Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HALOS: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION582 in Patients With Angelman Syndrome

Next Previous
X
Search
Trial Profile

HALOS: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION582 in Patients With Angelman Syndrome

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ION 582 (Primary)
  • Indications Angelman syndrome
  • Focus Adverse reactions; First in man
  • Acronyms HALOS
  • Sponsors Ionis Pharmaceuticals

    • Most Recent Events

    • 06 Nov 2024 According to an Ionis Pharmaceuticals Media Release, At the FAST Global Science Summit this weekend (November 8-9), company will provide review data from the MAD portion of the HALOS trial.
    • 06 Nov 2024 According to an Ionis Pharmaceuticals Media Release, The End of Phase 2 meeting was supported by data from the Phase 2 open-label HALOS study and Following positive results for ION582 in the Phase 2 HALOS trial, company is pleased to have alignment with the FDA on the design of our Phase 3 REVEAL trial.
    • 22 Jul 2024 According to an Ionis Pharmaceuticals Media Release, detailed results will be presented in a company webcast today and at the 2024 Angelman Syndrome Foundation (ASF) Family Conference in Sandusky, Ohio on July 24, 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top